Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
CAR-T cells, re-directed to tumor-associated antigens (TAA), have shown promising results in clinical trials and some patients have even undergone complete tumor regression. However, current CAR-T cell therapy needs more careful balance between T-cell activation (ensure antitumor activity) and the potential of uncontrolled activation that may induce immunopathology. For example, rapid tumor cell clearance may induce cytokine release syndrome and tumor lysis syndrome, which are both dangerous complications during CAR-T therapy. On-target/off-tumor activation of CAR-T cells by low level expression of targets on non-malignant tissues has also been associated with many severe toxicity and even death in some cases. In order to control these adverse responses of T cell therapy, the Self-destruct CAR has been developed. Specifically, CAR-T cells are engineered to express self-destruct CAR through RNA electroporation or viral transduction. The self-destruct CAR plays as a molecular switch, which negatively controls the performance of T cell therapy through the elimination of CAR-T cells and further ensures the safety of T cell therapy. With a newly established platform to engineer T cells by RNA electroporation and viral transduction, Creative Biolabs provides the self-destruct CAR construction service for clients all over the world.
The self-destruct CAR has exhibited potent antitumor effects and improved safety in preclinical xenograft models of human mesothelioma and advanced leukemia. The off switch suicide gene, herpes simplex virus thymidine kinase (HSV-TK), can be clear CAR-T cells after or during the gene therapy trials. Another suicide gene, inducible human caspase 9, can also be induced by intravenous administration of FK506 binding protein (FK506BP) and remove CAR-T cells in animal experiments through apoptosis.
Creative Biolabs provides self-destruct CAR construction service for clients across the world. As a leading company in immunotherapy development, Creative Biolabs can provide various products and services related to CAR-T cell therapy. We provide services on the most advanced fourth generation CAR to work with our clients to develop more potent and safe CAR-T treatment methods.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
